- Division of Translational and Clinical Sciences – DTCS
- Oncology 2 – Translational Clinical – OTC
- Study Section:
- Mechanisms of Cancer Therapeutics - 2 Study Section – MCT2
Dr. Careen Tang-Toth (Careen Tang) serves as the Scientific Reviewer Officer at the Oncology 2 - Translational and Clinical Integrated study section.
Dr. Tang-Toth received her Ph.D. degree from Johns Hopkins University and did her postdoctoral training as an IRTA fellow within the Cell Biology and Metabolism Program at the NIH National Institute of Child Health and Human Development. Prior to joining CSR, Dr. Tang-Toth was an associate professor in the Department of Oncology and the principal investigator of Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, where she conducted cancer research for 19 years. Her research focused on the role of oncogenes and tumor suppressor and signaling networks in cancer progression and metastasis, and she worked to assess the therapeutic efficacy of targeted cancer therapies and elucidate the mechanisms of therapeutic resistance. She was the principal investigator for various peer reviewed research grants, including NIH (R01) grants, DOD and numerous foundations grants, and she also received funding from pharmaceutical companies. Dr. Tang-Toth published over 60 original and review articles. She has trained many M.S. and Ph.D. graduate students and post-doctoral fellows in her laboratory. She was a chartered member of an NIH study section and also served as an temporary reviewer on numerous NIH, DOD and Susan Komen Foundation review groups.